Inge K. Bear

Chief Development Officer

Ms. Bear possesses over 30 years of clinical research experience in the life science industry, including cross-functional leadership in biopharmaceutical drug development from IND-enabling studies through filing of new drug applications (NDAs).  Prior to joining Leading BioSciences, she served as the chief development officer (CDO) at, a global marketplace company offering services and resources within the life science research and development industry.  Ms. Bear was previously the vice president of clinical operations and development at La Jolla Pharmaceutical Company, where she is credited with playing a pivotal role in the development and approval of Giapreza™ for the treatment of hypotensive shock.  She has held multiple operational and development leadership roles at several additional drug development companies, including Kalypsys, Inc., Ambrx, Inc., CovX Research, MediGene, Inc. and Vical, Inc. In these roles, Ms. Bear was integral in guiding and/or overseeing clinical operations, including the execution of clinical trials supporting the development of novel therapeutic candidates.  She has also served in key leadership roles at highly regarded contract research organizations, including INC Research (now known as Syneos Health), and Quintiles (now known as IQVIA).

Ms. Bear earned bachelor of art degrees in political science and history from the University of California, Berkeley, and a master’s degree in applied physiology from Finch University of Health Sciences, Chicago Medical School.